Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the use of a specific type of inhaled medication, called long-acting ß-2 mimetics, to see if it can help prevent breathing problems after lung surgery in patients who are at high risk for these issues. The researchers want to find out if giving this inhaled therapy during the time around the surgery can make a difference in how well patients recover and whether they experience complications related to their lungs after the procedure.

To be eligible for this study, participants need to be adults over 18 years old who have been diagnosed with non-small cell lung cancer and are planning to have surgery to remove part of their lung. It's important that they haven't used long-term inhaled medications before and that they have a lower lung function, which puts them at a higher risk for problems after surgery. The trial is not yet recruiting participants, but if someone meets these criteria, they could play a key role in helping researchers understand if this inhaled therapy can improve recovery after lung surgery. Participants will be monitored closely throughout the study, and their health will be regularly assessed to understand how well the treatment works.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (\>18 years)
• • Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route
• • Naïve to long-term inhaled bronchodilator therapy
• • High risk of post-operative pulmonary complications (Pre-operative FEV1 \< 80%)
• Exclusion Criteria:
• • Patient refusal
• • Pregnancy
• • Emergency surgery
• • Patient with a physiological status of WHO IV or ASA ≥ IV
• • Asthma
• • Patients treated with long-acting bronchodilators
• • Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction \< 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke \< 3 months
• • High-grade unresponsive conductive disorders or unstable arrhythmia
• • Thyrotoxicosis, pheochromocytoma
• • Unbalanced diabetes
• • Hypersensitivity to ß-2 mimetics or lactose
• • Current participation in a trial of another drug therapy